Gilead Sciences — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Gilead Sciences appears in 482 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials482

Recruiting shown10

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Study of GS-0415 and How It Works in People With HIVNCT07719491 · lead sponsor · 2026-07-22

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961 · lead sponsor · 2026-07-14

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778 · lead sponsor · 2026-03-17

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNCT06926920 · lead sponsor · 2025-04-30

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · lead sponsor · 2025-04-04

First in Human Study of TUB-030 in Patients With Advanced Solid TumorsNCT06657222 · lead sponsor · 2024-12-13

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)NCT06562907 · lead sponsor · 2024-08-28

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsNCT06337032 · lead sponsor · 2024-08-27

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCNCT06303505 · lead sponsor · 2024-06-12

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · lead sponsor · 2022-12-12

Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung CancerNCT07806773 · lead sponsor · 2026-11-01

NOT_YET_RECRUITING

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451 · lead sponsor · 2025-08-12

ACTIVE_NOT_RECRUITING

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716 · lead sponsor · 2025-07-22

ACTIVE_NOT_RECRUITING

Study of GS-0151 in Participants With Rheumatoid ArthritisNCT06902519 · lead sponsor · 2025-05-14

ACTIVE_NOT_RECRUITING

A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in SpainNCT06683482 · lead sponsor · 2025-02-21

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · lead sponsor · 2024-10-07

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · lead sponsor · 2023-12-13

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · lead sponsor · 2023-11-17

ACTIVE_NOT_RECRUITING

Study of GS-0272 in Participants With Rheumatoid ArthritisNCT06031415 · lead sponsor · 2023-09-28

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · lead sponsor · 2023-05-08

ACTIVE_NOT_RECRUITING

Study of Novel Treatment Combinations in Patients With Lung CancerNCT05633667 · lead sponsor · 2023-03-16

ACTIVE_NOT_RECRUITING

Study With Various Immunotherapy Treatments in Participants With Lung CancerNCT05676931 · lead sponsor · 2023-02-21

ACTIVE_NOT_RECRUITING

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237 · lead sponsor · 2022-10-12

ACTIVE_NOT_RECRUITING

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsNCT05458102 · lead sponsor · 2022-08-19

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · lead sponsor · 2022-07-25

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · lead sponsor · 2022-07-20

ACTIVE_NOT_RECRUITING

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) TreatmentNCT05165771 · lead sponsor · 2022-07-01

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenNCT05281510 · lead sponsor · 2022-06-09

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974 · lead sponsor · 2022-05-30

ACTIVE_NOT_RECRUITING

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04958785 · lead sponsor · 2021-12-14

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734 · lead sponsor · 2021-11-17

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096 · lead sponsor · 2021-10-20

ACTIVE_NOT_RECRUITING

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996 · lead sponsor · 2021-10-05

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509 · lead sponsor · 2021-08-30

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionNCT04925752 · lead sponsor · 2021-06-28

ACTIVE_NOT_RECRUITING

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986 · lead sponsor · 2020-11-23

ACTIVE_NOT_RECRUITING

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsNCT04608344 · lead sponsor · 2020-11-04

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsNCT04454437 · lead sponsor · 2020-10-23

ACTIVE_NOT_RECRUITING

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594 · lead sponsor · 2019-11-22

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165 · lead sponsor · 2019-07-24

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645 · lead sponsor · 2019-06-28

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerNCT03901339 · lead sponsor · 2019-05-08

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866 · lead sponsor · 2018-11-26

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionNCT03417778 · lead sponsor · 2018-04-03

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusNCT03472326 · lead sponsor · 2018-04-03

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455 · lead sponsor · 2017-11-07

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380 · lead sponsor · 2017-06-12

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447 · lead sponsor · 2017-05-09

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeNCT03100942 · lead sponsor · 2017-05-01

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerNCT02983604 · lead sponsor · 2017-01-10

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisNCT02862574 · lead sponsor · 2016-12-15

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateNCT02885181 · lead sponsor · 2016-09-21

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02889796 · lead sponsor · 2016-08-30

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyNCT02886728 · lead sponsor · 2016-08-08

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerNCT02161679 · lead sponsor · 2016-08-01

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentNCT02873936 · lead sponsor · 2016-07-27

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601 · lead sponsor · 2016-04-01

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)NCT02626026 · lead sponsor · 2016-01-26

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsNCT02616783 · lead sponsor · 2015-12-22

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerNCT02607228 · lead sponsor · 2015-12-08

Drugs studied in this sponsor's trials

125 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Gilead Sciences as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo29

sacituzumab govitecan22

ambrisentan16

ranolazine15

pembrolizumab14

adefovir dipivoxil11

carboplatin11

Truvada11

placebo RxCUI 8375 · Lead sponsor in 23 linked trial(s) · 1 currently recruiting 29 trials sacituzumab govitecan RxCUI 2360232 · Lead sponsor in 1 linked trial(s) · 9 currently recruiting 22 trials ambrisentan RxCUI 358274 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 16 trials ranolazine RxCUI 35829 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 15 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 4 linked trial(s) · 4 currently recruiting 14 trials adefovir dipivoxil RxCUI 141400 · Lead sponsor in 11 linked trial(s) · 0 currently recruiting 11 trials carboplatin RxCUI 40048 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 11 trials Truvada RxCUI 495430 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 11 trials Stribild RxCUI 1306293 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 10 trials tenofovir disoproxil fumarate RxCUI 322248 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 10 trials sacituzumab govitecan-hziy RxCUI 2360530 · Lead sponsor in 8 linked trial(s) · 1 currently recruiting 9 trials paclitaxel RxCUI 56946 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 8 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 7 linked trial(s) · 1 currently recruiting 8 trials cidofovir RxCUI 83171 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 7 trials pemetrexed RxCUI 68446 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 7 trials ribavirin RxCUI 9344 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials ritonavir RxCUI 85762 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 7 trials capecitabine RxCUI 194000 · Lead sponsor in 4 linked trial(s) · 2 currently recruiting 6 trials cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 6 trials efavirenz RxCUI 195085 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 6 trials lenacapavir Injection RxCUI 2625903 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 6 trials gemcitabine RxCUI 12574 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials metformin RxCUI 6809 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 5 trials zidovudine RxCUI 11413 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials

Sponsor roles

collaborator268

lead sponsor214

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.